Recently, the French World Nuclear Industry Expo (WNE2023) was held in the northern suburbs of Paris. This expo event is unprecedented, attracting more than 650 exhibitors and more than 20,000 participants in related fields of the global nuclear industry. China, France, the United States, the United Kingdom, South Korea, the Czech Republic and other 17 major participating countries in the world nuclear industry set up national exhibition areas in the exhibition, and CNNC Group appeared in the central position of the China exhibition area.
In the CNNC exhibition area, the civil non-power nuclear technology application sector has a monopoly on one side, showing the world the comprehensive capabilities of CNNC in the whole industrial chain in the fields of radiotherapy, nuclear medicine and radiopharma, radiation processing, as well as the strength and determination to provide integrated solutions for global customers. A lot of visitors came to visit the exhibition area and received good publicity effect.
Ma Wenjun (1st left), Deputy General manager of CNNC, and Shen Lixin (3rd left), Deputy Director of the Industrial Development and International Cooperation Department of CNNC, introduce radioactive drugs to Chen Li (2nd left), Minister of the Chinese Embassy in France
HTA's radiopharmaceutical model was exhibited at the conference for the first time, attracting participants from all over the world to visit and exchange, and many participants said that they had learned about China's achievements in the industry and its ability to provide services to the outside world for the first time, hoping to cooperate with related enterprises. Among them, the head of scientific research and project feasibility study of the Department of Atomic Energy of the Saudi Nuclear and Renewable Energy City K.A.ARE (Saudi government agency in charge of renewable energy) visited the exhibition area and showed strong interest in CNNC's industry-wide comprehensive capabilities covering the upper, middle and lower reaches of the isotope and radiopharmaceutical supply chain. The Saudi government is investigating potential suppliers of integrated solutions for the industry worldwide, and is committed to enhancing Saudi Arabia's autonomy in the field of radiopharmaceuticals in order to provide better protection for the life and health of its people. During the conference, HTA also held talks with participants from other countries about potential cooperation.
The front page of the special issue of the conference highlights the important role of radionuclides in cancer diagnosis and treatment, and describes the interest and increasing investment of the world's nuclear energy companies in this field. As a leading enterprise in China's pharmaceutical industry, HTA will always uphold the corporate purpose of "developing nuclear drugs for the benefit of mankind", constantly enhance the core competitiveness of the enterprise, accelerate the process of international business reform, and strive to make the "nuclear energy" in the medical field play a greater energy to bring health to more countries and regions in the world.
